#Top3Words: How would you describe Castle's culture? EXCITEMENT is one of the words Micah Bires (Digital Marketing Associate) talks about when describing #CastleCulture: "People have such a great energy about what we're doing and people are passionate about the vision of Castle..." #TeamCastle #CastleCareers #WeLoveOurPeople❤️

🎉Congratulations to Dr. Matthew Goldberg, Castle's Senior Vice President of Medical, for being named to the prestigious Power List by The Pathologist for the second year in a row! The Power List 2026 celebrates the people whose ideas, expertise, and leadership are helping to shape the future of pathology and laboratory medicine. Judges selected the top 50 individuals they believe are doing the most to effect positive change across pathology and laboratory medicine. The Power List 2026: hubs.la/Q04BlFLd0

#CastleCulture is focused on putting PEOPLE FIRST: patients, clinicians, employees, and investors. We asked Castle team members: How does your role at Castle make an impact on people? In this video, hear perspectives from Serra Bauer (Area Manager) and Jason March (Senior Product Director), both passionate about how their work with #TissueCypher impacts patients and clinicians. #PeopleFirst #TeamCastle #CastleCareers #WeLoveOurPeople❤️

TOMORROW, 10/14: Castle Biosciences' Chief of Staff Hillary Caruso will be speaking on a panel, "Reimbursement: What Does It Take to Get Paid for Innovation?" at the ASU National Diagnostics Summit (10:45 - 11:30 AM Arizona time). Moderated by Michael Ryan (McDermott Will & Emery), the panel also includes Molly Broache (Illumina), Lena Chaihorsky (Alva10), and Danielle Scelfo (Baylor Genetics). Registration is free, so join live, either in person at Old Main on the ASU Tempe campus or via Zoom: hubs.la/Q04B14870 #ASUDxSummit #Diagnostics #HealthInnovation

Castle is presenting NEW DATA from three studies evaluating its TissueCypher Barrett's Esophagus (BE) test at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and Postgraduate Course, taking place Oct. 9-14 in Nashville, Tennessee. The studies include two case reports and one multi-center study highlighting how TissueCypher can provide additional risk information beyond histopathology to support risk-aligned patient management decisions. Details/highlights: hubs.la/Q04zYlnP0

#FallIntoHealthyHabits: Ocular Edition Happy #WorldSightDay! When it comes to staying healthy, we can't forget our 👀 EYES! Many eye diseases, such as uveal melanoma (the most common form of eye cancer), can have no symptoms, so regular exams — including dilated eye exams — are critical to early diagnosis. #LoveYourEyes #UvealMelanoma #OcularMelanoma #DecisionDxUM

🎉We're celebrating! Castle was recently recognized as a Top Workplace in Pittsburgh, ranking 3rd among large companies with more than 400 employees nationally. This recognition is especially meaningful because it reflects the experiences and voices of Castle employees. As an additional achievement, Castle was honored with the Meaningfulness Award, recognizing our team's outstanding response to the employee engagement survey statement: “My job makes me feel like I am part of something meaningful.” Representing #TeamCastle: Alicia Angelo, Danyale Strider, and Jamie Bleicher #TopWorkplaces #CastleCulture

#WhyCastle #TeamCastle members Tabby Smith and Robert Poolsawat weigh in on why they love working at Castle... "...No matter how big or small your role, we all play a part in making a difference." "...The culture here is real. It's not just a tagline." #CastleCulture #CastleCareers #WeLoveOurPeople❤️

Castle announces the publication of a study showing that the TissueCypher® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE). In the study, clinicians changed their management recommendations 90% of the time after receiving TissueCypher results, including escalating management for all patients with intermediate- or high-risk results and de-escalating management for 84% of those with low-risk results. The study, titled "The Tissue Systems Pathology Test Guides Physician Recommendations for Patients With Non-Dysplastic Barrett's Esophagus: A Case Series From a Gastrointestinal Surgery Center," was published in Foregut: The Journal of the American Foregut Society and is linked in the press release: hubs.la/Q04yBtbh0

Castle announces the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selection. "One thing came through clearly in this study: patients want better control of their disease and more information to help guide their treatment decisions," said study author Diego Ruiz Dasilva, M.D., board-certified dermatologist at Forefront Dermatology in Virginia Beach, Virginia. "AdvanceAD-Tx gives us an opportunity to bring objective molecular information into those conversations, helping personalize systemic treatment decisions and expedite the path to an effective therapy and symptom relief." Press Release: hubs.la/Q04ykTRl0